Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Skrypek

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Biochimica Et Biophysica Acta|May 3, 2014
Mucins and tumor resistance to chemotherapeutic drugsNicolas Jonckheere, Nicolas Skrypek, Isabelle Van Seuningen
Cancers|November 28, 2013
Mucins and pancreatic cancerNicolas Jonckheere, Nicolas Skrypek, Isabelle Van Seuningen
Biochimie|November 27, 2012
Membrane-bound mucin modular domains: from structure to functionNicolas Jonckheere, Nicolas Skrypek, Frédéric Frénois, et al.
Trends in Genetics : TIG|September 19, 2017
Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular PlasticityNicolas Skrypek, Steven Goossens, Eva De Smedt, et al.
Oncotarget|April 20, 2015
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2Nicolas Skrypek, Romain Vasseur, Audrey Vincent, et al.
Molecular Cancer Research : MCR|July 20, 2022
DNA Methyltransferase 3B-Mediated Intratumoral Heterogeneity and Therapeutic Targeting in Breast Cancer Recurrence and MetastasisJae Young So, Howard H Yang, Woo Yong Park, et al.
Epigenetics & Chromatin|November 18, 2018
ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transitionNicolas Skrypek, Kenneth Bruneel, Cindy Vandewalle, et al.
Biochimica Et Biophysica Acta|October 20, 2015
The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathwaysRomain Vasseur, Nicolas Skrypek, Belinda Duchêne, et al.
Cancers|August 2, 2018
TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727Vincent Drubay, Nicolas Skrypek, Lucie Cordiez, et al.
Plos One|March 7, 2012
The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathwaysNicolas Jonckheere, Nicolas Skrypek, Johann Merlin, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Biochimica Et Biophysica Acta|May 3, 2014
Mucins and tumor resistance to chemotherapeutic drugsNicolas Jonckheere, Nicolas Skrypek, Isabelle Van Seuningen
Cancers|November 28, 2013
Mucins and pancreatic cancerNicolas Jonckheere, Nicolas Skrypek, Isabelle Van Seuningen
Biochimie|November 27, 2012
Membrane-bound mucin modular domains: from structure to functionNicolas Jonckheere, Nicolas Skrypek, Frédéric Frénois, et al.
Trends in Genetics : TIG|September 19, 2017
Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular PlasticityNicolas Skrypek, Steven Goossens, Eva De Smedt, et al.
Oncotarget|April 20, 2015
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2Nicolas Skrypek, Romain Vasseur, Audrey Vincent, et al.
Molecular Cancer Research : MCR|July 20, 2022
DNA Methyltransferase 3B-Mediated Intratumoral Heterogeneity and Therapeutic Targeting in Breast Cancer Recurrence and MetastasisJae Young So, Howard H Yang, Woo Yong Park, et al.
Epigenetics & Chromatin|November 18, 2018
ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transitionNicolas Skrypek, Kenneth Bruneel, Cindy Vandewalle, et al.
Biochimica Et Biophysica Acta|October 20, 2015
The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathwaysRomain Vasseur, Nicolas Skrypek, Belinda Duchêne, et al.
Cancers|August 2, 2018
TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727Vincent Drubay, Nicolas Skrypek, Lucie Cordiez, et al.
Plos One|March 7, 2012
The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathwaysNicolas Jonckheere, Nicolas Skrypek, Johann Merlin, et al.
Pageof 2